Bristol Operating Income from 2010 to 2024

BMY Stock

USD 47.84 0.42 0.87%

Bristol Myers Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Bristol Myers Squibb generates from its operations. View All Fundamentals

Operating Income

First Reported

1987-03-31

Previous Quarter

4.2 B

Current Value

1.7 B

Quarterly Volatility

1.2 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.2 B, Interest Expense of 1.2 B or Selling General Administrative of 8.4 B, as well as many exotic indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0374 or PTB Ratio of 6.92. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.

This module can also supplement Bristol Myers' financial leverage analysis and stock options assessment as well as various Bristol Myers Technical models . Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Operating Income Growth Pattern

Below is the plot of the Operating Income of Bristol Myers Squibb over the last few years. Operating Income is the amount of profit realized from Bristol Myers Squibb operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Bristol Myers Squibb is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Bristol Myers' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Bristol Operating Income Regression Statistics

	Arithmetic Mean	6,530,206,667
	Geometric Mean	4,927,433,879
	Coefficient Of Variation	80.45
	Mean Deviation	3,977,208,889
	Median	5,118,000,000
	Standard Deviation	5,253,782,876
	Sample Variance	27602234.5T
	Range	16.6B
	R-Value	0.79
	Mean Square Error	11266640.7T
	R-Squared	0.62
	Significance	0.0005
	Slope	925,752,500
	Total Sum of Squares	386431283.2T

Bristol Operating Income History

	2024	18.1 B
	2023	17.2 B
	2022	10.3 B
	2021	10.2 B
	2020	5.1 B
	2019	5.5 B
	2018	5.1 B

Other Fundumenentals of Bristol Myers Squibb

Non Operating Income Net Other

Bristol Myers Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.89	0.98	-0.07	0.76	0.97	0.99	0.94	0.85	0.96	0.6	0.12	0.88	0.88	0.98	-0.76	0.83	0.68	-0.97	0.37	0.97	0.93	0.79	-0.5	-0.35	0.91	0.98	0.86
Total Stockholder Equity	0.89		0.84	0.13	0.5	0.82	0.85	0.76	0.73	0.93	0.62	0.36	0.81	0.81	0.85	-0.51	0.73	0.52	-0.87	0.28	0.81	0.73	0.82	-0.51	-0.31	0.83	0.89	0.79
Net Debt	0.98	0.84		-0.17	0.82	0.98	0.99	0.93	0.89	0.95	0.56	-0.02	0.91	0.91	0.99	-0.82	0.87	0.71	-0.99	0.44	0.99	0.97	0.76	-0.54	-0.37	0.93	0.98	0.85
Retained Earnings	-0.07	0.13	-0.17		-0.11	-0.03	-0.11	-0.05	-0.16	-0.13	0.44	0.49	-0.15	-0.15	-0.17	0.05	-0.07	-0.59	0.19	-0.45	-0.23	-0.26	-0.07	0.43	-0.13	-0.21	-0.19	-0.16
Net Receivables	0.76	0.5	0.82	-0.11		0.88	0.8	0.86	0.87	0.62	0.53	-0.15	0.81	0.81	0.8	-0.98	0.84	0.52	-0.75	0.54	0.82	0.9	0.33	-0.35	-0.51	0.73	0.75	0.63
Good Will	0.97	0.82	0.98	-0.03	0.88		0.98	0.95	0.9	0.9	0.63	0.03	0.9	0.9	0.97	-0.88	0.88	0.63	-0.95	0.41	0.97	0.97	0.7	-0.47	-0.42	0.9	0.95	0.82
Total Liab	0.99	0.85	0.99	-0.11	0.8	0.98		0.96	0.87	0.95	0.61	0.05	0.9	0.9	0.99	-0.81	0.85	0.68	-0.98	0.4	0.98	0.95	0.77	-0.51	-0.37	0.93	0.97	0.86
Total Current Assets	0.94	0.76	0.93	-0.05	0.86	0.95	0.96		0.85	0.84	0.68	0.07	0.86	0.86	0.94	-0.86	0.81	0.63	-0.89	0.37	0.94	0.94	0.61	-0.4	-0.36	0.87	0.9	0.82
Short Term Debt	0.85	0.73	0.89	-0.16	0.87	0.9	0.87	0.85		0.82	0.53	0.05	0.84	0.84	0.87	-0.83	0.85	0.59	-0.87	0.57	0.87	0.9	0.6	-0.48	-0.43	0.87	0.88	0.75
Intangible Assets	0.96	0.93	0.95	-0.13	0.62	0.9	0.95	0.84	0.82		0.5	0.17	0.84	0.84	0.95	-0.62	0.78	0.7	-0.97	0.4	0.94	0.87	0.88	-0.63	-0.33	0.93	0.98	0.87
Accounts Payable	0.6	0.62	0.56	0.44	0.53	0.63	0.61	0.68	0.53	0.5		0.19	0.64	0.64	0.56	-0.61	0.6	0.01	-0.54	-0.13	0.52	0.51	0.39	-0.01	-0.13	0.5	0.51	0.4
Short Term Investments	0.12	0.36	-0.02	0.49	-0.15	0.03	0.05	0.07	0.05	0.17	0.19		-0.04	-0.04	0.04	0.21	-0.1	-0.09	-0.02	-0.17	-0.02	-0.09	0.24	0.09	-0.05	0.16	0.1	0.3
Capital Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.84	0.64	-0.04		1.0	0.9	-0.83	0.95	0.69	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Common Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.84	0.64	-0.04	1.0		0.9	-0.83	0.95	0.69	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Long Term Debt	0.98	0.85	0.99	-0.17	0.8	0.97	0.99	0.94	0.87	0.95	0.56	0.04	0.9	0.9		-0.8	0.85	0.72	-0.99	0.45	1.0	0.96	0.76	-0.58	-0.4	0.96	0.99	0.89
Treasury Stock	-0.76	-0.51	-0.82	0.05	-0.98	-0.88	-0.81	-0.86	-0.83	-0.62	-0.61	0.21	-0.83	-0.83	-0.8		-0.87	-0.51	0.76	-0.41	-0.81	-0.9	-0.37	0.31	0.4	-0.7	-0.74	-0.59
Property Plant Equipment	0.83	0.73	0.87	-0.07	0.84	0.88	0.85	0.81	0.85	0.78	0.6	-0.1	0.95	0.95	0.85	-0.87		0.62	-0.86	0.54	0.86	0.89	0.64	-0.55	-0.47	0.8	0.84	0.72
Current Deferred Revenue	0.68	0.52	0.71	-0.59	0.52	0.63	0.68	0.63	0.59	0.7	0.01	-0.09	0.69	0.69	0.72	-0.51	0.62		-0.72	0.53	0.77	0.77	0.61	-0.59	-0.11	0.71	0.76	0.78
Net Tangible Assets	-0.97	-0.87	-0.99	0.19	-0.75	-0.95	-0.98	-0.89	-0.87	-0.97	-0.54	-0.02	-0.9	-0.9	-0.99	0.76	-0.86	-0.72		-0.44	-0.98	-0.94	-0.83	0.6	0.35	-0.95	-0.99	-0.86
Total Permanent Equity	0.37	0.28	0.44	-0.45	0.54	0.41	0.4	0.37	0.57	0.4	-0.13	-0.17	0.46	0.46	0.45	-0.41	0.54	0.53	-0.44		0.49	0.52	0.17	-0.75	-0.76	0.51	0.48	0.45
Long Term Debt Total	0.97	0.81	0.99	-0.23	0.82	0.97	0.98	0.94	0.87	0.94	0.52	-0.02	0.91	0.91	1.0	-0.81	0.86	0.77	-0.98	0.49		0.98	0.74	-0.6	-0.39	0.95	0.98	0.89
Capital Surpluse	0.93	0.73	0.97	-0.26	0.9	0.97	0.95	0.94	0.9	0.87	0.51	-0.09	0.92	0.92	0.96	-0.9	0.89	0.77	-0.94	0.52	0.98		0.65	-0.56	-0.37	0.9	0.95	0.82
Deferred Long Term Liab	0.79	0.82	0.76	-0.07	0.33	0.7	0.77	0.61	0.6	0.88	0.39	0.24	0.64	0.64	0.76	-0.37	0.64	0.61	-0.83	0.17	0.74	0.65		-0.51	-0.11	0.76	0.8	0.78
Long Term Investments	-0.5	-0.51	-0.54	0.43	-0.35	-0.47	-0.51	-0.4	-0.48	-0.63	-0.01	0.09	-0.52	-0.52	-0.58	0.31	-0.55	-0.59	0.6	-0.75	-0.6	-0.56	-0.51		0.55	-0.65	-0.63	-0.6
Short Long Term Debt	-0.35	-0.31	-0.37	-0.13	-0.51	-0.42	-0.37	-0.36	-0.43	-0.33	-0.13	-0.05	-0.35	-0.35	-0.4	0.4	-0.47	-0.11	0.35	-0.76	-0.39	-0.37	-0.11	0.55		-0.46	-0.38	-0.39
Cash And Equivalents	0.91	0.83	0.93	-0.21	0.73	0.9	0.93	0.87	0.87	0.93	0.5	0.16	0.86	0.86	0.96	-0.7	0.8	0.71	-0.95	0.51	0.95	0.9	0.76	-0.65	-0.46		0.96	0.94
Net Invested Capital	0.98	0.89	0.98	-0.19	0.75	0.95	0.97	0.9	0.88	0.98	0.51	0.1	0.9	0.9	0.99	-0.74	0.84	0.76	-0.99	0.48	0.98	0.95	0.8	-0.63	-0.38	0.96		0.89
Net Working Capital	0.86	0.79	0.85	-0.16	0.63	0.82	0.86	0.82	0.75	0.87	0.4	0.3	0.78	0.78	0.89	-0.59	0.72	0.78	-0.86	0.45	0.89	0.82	0.78	-0.6	-0.39	0.94	0.89

Click cells to compare fundamentals

About Bristol Myers Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Bristol Myers investors use historical funamental indicators, such as Bristol Myers's Operating Income, to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol Myers Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	17.2 B	18.1 B
Non Operating Income Net Other	-662.4 M	-629.3 M

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

0.77	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr
0.62	EQ	Equillium Financial Report 9th of May 2024	Pair Corr

Moving against Bristol Stock

0.62	KA	Kineta Inc Financial Report 9th of May 2024	Pair Corr
0.6	DMTK	DermTech Financial Report 2nd of May 2024	Pair Corr
0.56	DRUG	Bright Minds Biosciences	Pair Corr
0.51	ME	23Andme Holding	Pair Corr
0.46	VALN	Valneva SE ADR Financial Report 2nd of May 2024	Pair Corr

The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.

The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:

How To Invest In Bristol

Details

Is Bristol Stock a good investment?

Details

What is Bristol Myers' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Bristol Myers Correlation against competitors.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Bonds Directory Find actively traded corporate debentures issued by US companies

Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.09)

Dividend Share

2.31

Earnings Share

3.86

Revenue Per Share

21.753

Quarterly Revenue Growth

0.006

The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Operating Income from 2010 to 2024

Latest Bristol Myers' Operating Income Growth Pattern

Bristol Operating Income Regression Statistics

Bristol Operating Income History

Other Fundumenentals of Bristol Myers Squibb

Bristol Myers Operating Income component correlations

About Bristol Myers Financial Statements

Pair Trading with Bristol Myers

Moving together with Bristol Stock

Moving against Bristol Stock

Complementary Tools for Bristol Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY